Key mechanism of resistance to BRAF-targeted melanoma therapy discovered. Potential for developing new cancer therapies with high efficacy by regulating polyamine biosynthesis to suppress resistance.
Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient ...
gordonii releases a substance called ornithine that prompts F. nucleatum to produce a molecule called polyamine in larger quantities. Since F. nucleatum requires methionine to produce polyamine, this ...